The Ofix 200 Tablet is a prescription fluoroquinolone antibiotic containing 200mg of ofloxacin as its active pharmaceutical ingredient. It is primarily utilized by physicians to treat susceptible bacterial infections, including lower and upper respiratory tract infections (like pneumonia and bronchitis), urinary tract infections, skin and soft tissue infections, and chronic bacterial prostatitis. It works by inhibiting essential bacterial enzymes (DNA gyrase and topoisomerase IV) required for bacterial replication and survival.
Yes, Medicare generally covers bone growth stimulators, but coverage is strictly regulated and contingent upon meeting precise medical necessity criteria.
Clinical studies evaluating non-invasive bone growth stimulators (which utilize pulsed electromagnetic field or low-intensity ultrasound technology to promote healing in non-union fractures or spinal fusions) generally report high clinical success ra...
Wall Street equity research analysts covering Orthofix Medical Inc. (NASDAQ: OFIX) maintain a general consensus rating leaning toward a Buy.
The corporate net worth or market capitalization of Orthofix Medical Inc. (NASDAQ: OFIX) fluctuates dynamically during active trading hours on the Nasdaq exchange based on share price changes and total outstanding common stock.
The cost of an Orthofix bone growth stimulator (such as their proprietary spine or extremity therapy units) varies depending on insurance contractual agreements, Medicare fee schedules, and whether the device is rented or purchased.
Revo Health operates as a prominent management services organization partnering with specialized healthcare practices like Twin Cities Orthopedics.
Bone growth stimulators are generally considered exceptionally safe medical devices with minimal adverse side effects.
Yes, Medicare generally covers non-invasive bone growth stimulators, but authorization is strictly contingent upon meeting precise medical necessity criteria.
Orthofix Medical Inc.
Orthofix Inc. previously faced high-profile federal scrutiny and a major whistleblower False Claims Act lawsuit that resulted in a $42 million global criminal and civil resolution with the U.S. Department of Justice.
The out-of-pocket rental cost for a prescription bone growth stimulator varies significantly depending on health insurance coverage, Medicare provider fee schedules, and specific device models.
Orthofix Medical Inc. is recognized as an established global medical technology enterprise dedicated to advancing spine and orthopedic care solutions.
No, Orthofix Medical Inc. is not a private company. It is a publicly traded global medical technology enterprise listed on the Nasdaq Global Select Market under the ticker symbol OFIX.
When discussing medical devices or orthopedic care frameworks, "Safix" (or similar variant terminology associated with casting, bandaging, or stabilization products) typically presents minimal localized risks.
The global orthopedic and medical device market features several massive multinational corporations competing for top market share.
The financial cost of an Orthofix bone growth stimulator varies substantially depending on whether the device is rented or purchased, insurance contract terms, and specific Medicare fee schedules.
Orthofix Medical Inc. (NASDAQ: OFIX) generates robust annual net revenues scaling in the hundreds of millions of dollars, typically reporting total yearly revenues between $700 million and $750 million.
The prescribed duration for wearing a non-invasive bone growth stimulator varies significantly based on the specific anatomical location of the fracture, the severity of the non-union or spinal fusion, and the attending physician's clinical instructi...
Supporting bone fracture healing and overall skeletal health through nutrition requires adequate intake of calcium, protein, and essential micronutrients.
Orthofix Medical Inc.
Prescription bone growth stimulators are high-end medical devices, with retail purchase costs or monthly commercial rental fees ranging broadly from $2,000 to over $4,000 per month depending on the specific model and treatment duration required.
Orthofix Medical Inc. maintains its primary corporate headquarters and executive administrative offices in Lewisville, Texas, United States.
Orthofix Medical Inc. maintains a dedicated global workforce comprising approximately 1,300 to 1,600 employees worldwide.
In orthopedic and medical device contexts, specialized systems carrying similar names are deployed to stimulate bone healing.
The President and Chief Executive Officer of Orthofix Medical Inc. is Massimo Calafiore, who also serves as a member of the company's Board of Directors.